TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma.
Alberto PiccaAnna Luisa Di StefanoJulien SavatovskyFrançois DucrayOlivier ChinotElisabeth Cohen-Jonathan MoyalPaule AugereauEmilie Le RhunYohann SchmittNabila RousseauxAriane Murielle Mbekwe YepnangCandice EstellatFrédérique CharbonneauQuentin LetourneurDominique Figarella BrangerDavid MeyronetChristine FardeauKarima MokhtariFranck BielleAntonio IavaroneMarc SansonPublished in: Neuro-oncology advances (2024)
Fexagratinib exhibited acceptable toxicity but limited efficacy in recurrent FGFR3-TACC3 + HGGs. Patients treated at first recurrence appeared more likely to benefit, yet additional evidence is required.